Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ATMPs

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

- PMLiVE

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

New funding will help London build on its gene therapy expertise

- PMLiVE

Freeline raises £88m to accelerate haemophilia gene therapy

Spin-out from London university joins fast-developing field

EU flag

UK pharma cheers EU science announcement

UK won't be excluded from Horizon research collaboration

- PMLiVE

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Orphan drug sales growth will be 11%+ a year

- PMLiVE

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Big departure from repurposing - Spark's Fraser Wright comes on board

- PMLiVE

Europe’s public-private alliance targets pain management

Innovative Medicines Initiative (IMI) brings pharma together with academia and patient groups in underserved area

- PMLiVE

Pharma sees European generics export plan as anti-innovation

EFPIA condemns plans - but European Commission says changes would create jobs in Europe

- PMLiVE

More encouraging data for Spark and Pfizer’s potential haemophilia B cure

Pfizer set to commence phase III trials

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

New centre aims to Catapult UK into cell and gene therapy lead

The UK is hoping to cement its lead as a world leader in cell and gene therapy manufacturing thanks to a new ‘Catapult’ centre opened today.

- PMLiVE

EU’s first health report card – must do better

Report implies Europe must shift its focus to disease prevention

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links